- Home
- VSTM vs SGMO Comparison
VSTM vs SGMO Comparison
Compare VSTM & SGMO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VSTM
- SGMO
- Stock Information
- Founded
- VSTM 2010
- SGMO 1995
- Country
- VSTM United States
- SGMO United States
- Employees
- VSTM N/A
- SGMO N/A
- Industry
- VSTM Biotechnology: Pharmaceutical Preparations
- SGMO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- VSTM Health Care
- SGMO Health Care
- Exchange
- VSTM Nasdaq
- SGMO Nasdaq
- Market Cap
- VSTM 263.5M
- SGMO 242.0M
- IPO Year
- VSTM 2012
- SGMO 2000
- Fundamental
- Price
- VSTM $7.20
- SGMO $0.96
- Analyst Decision
- VSTM Strong Buy
- SGMO Buy
- Analyst Count
- VSTM 8
- SGMO 6
- Target Price
- VSTM $12.67
- SGMO $5.17
- AVG Volume (30 Days)
- VSTM 806.1K
- SGMO 3.6M
- Earning Date
- VSTM 03-21-2025
- SGMO 03-17-2025
- Dividend Yield
- VSTM N/A
- SGMO N/A
- EPS Growth
- VSTM N/A
- SGMO N/A
- EPS
- VSTM N/A
- SGMO N/A
- Revenue
- VSTM $10,000,000.00
- SGMO $52,291,000.00
- Revenue This Year
- VSTM N/A
- SGMO N/A
- Revenue Next Year
- VSTM $117.91
- SGMO N/A
- P/E Ratio
- VSTM N/A
- SGMO N/A
- Revenue Growth
- VSTM N/A
- SGMO N/A
- 52 Week Low
- VSTM $2.10
- SGMO $0.30
- 52 Week High
- VSTM $13.52
- SGMO $3.18
- Technical
- Relative Strength Index (RSI)
- VSTM 77.09
- SGMO 43.79
- Support Level
- VSTM $5.40
- SGMO $0.94
- Resistance Level
- VSTM $7.50
- SGMO $1.06
- Average True Range (ATR)
- VSTM 0.43
- SGMO 0.11
- MACD
- VSTM 0.19
- SGMO 0.02
- Stochastic Oscillator
- VSTM 97.38
- SGMO 53.05
About VSTM Verastem Inc.
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.
About SGMO Sangamo Therapeutics Inc.
Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its pipeline products include the Priority Neurology Pipeline offers Chronic Neuropathic Pain, Prion Disease, and Neurology; Partnered Programs offer Hemophilia A, Oncology, ALS/FTD, and Huntington's Disease; and Other Pipelines include Fabry Disease, Renal Transplant, Inflammatory Bowel Disease, and Multiple Sclerosis.